Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vero Cell-derived Influenza Vaccine Immunogenicity and Safety
NCT00161811Phase 3Completed
- Sponsor
- Resilience Government Services
- Start
- Nov 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of vero cell-derived influenza vaccine in influenza (4 arms), sponsored by Resilience Government Services. Primary endpoints: Immunogenicity at Day 180 and Safety at Day 180. Started Nov 2004; status: completed.
02
Drugs
vero cell-derived influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00161811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161811.